This website uses cookies to improve the site and user experience. By continuing to browse this site,
you agree to accept our use of cookies. For more information, please review our Cookies Policy
ASCO® Gastrointestinal Cancers Symposium 2022
Presentations

SEA-CD40 | Pancreatic Ductal Adenocarcinoma | Abstract #559
Preliminary results of a phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC)

Tucatinib | Solid Tumors | Abstract #TPS489
SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: biliary tract cancer cohort (Trial in Progress)

Tucatinib | Gastrointestinal Cancers | Abstract #TPS376
Phase 1b/2, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab with and without oxaliplatin-based chemotherapy or pembrolizumab in patients with unresectable or metastatic HER2+ gastrointestinal cancers (Trial in Progress)

Tucatinib | Gastrointestinal Carcinoma | Abstract #TPS371
MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in Progress